메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Xiang Wei (Department of Urology The Third Xiangya Hospital of Central South University) Peng Yongbo (Chongqing Key Laboratory for Pharmaceutical Metabolism Research the Key Laboratory of Biochemistry and Molecular Pharmacology College of Pharmacy Chongqing Medical University) Zeng Hongliang (Department of Urology The Third Xiangya Hospital of Central South University) Yu Chunping (Department of Urol ogy Sun Yat-sen University Cancer Center) Zhang Qun (Department of Radiotherapy The First Afliated Hospital of Sun Yat-sen University) Liu Biao (Department of Urology The Third Xiangya Hospital of Central South University) Liu Jiahao (Department of Urology The Third Xiangya Hospital of Central South University) Hu Xing (Department of Urology The Third Xiangya Hospital of Central South University) Wei Wensu (Department of Urology Sun Yat-sen University Cancer Center) Deng Minhua (Department of Urology Sun Yat-sen University Cancer Center) Wang Ning (Department of Urology Sun Yat-sen University Cancer Center) Liu Xuewen (Department of Onology The Third Xiangya Hospital of Central South University) Xie Jianfei (Department of Nursing The Third Xiangya Hospital of Central South University) Hou Weibin (Department of Urology The Third Xiangya Hospital of Central South University) Tang Jin (Department of Urology The Third Xiangya Hospital of Central South University) Long Zhi (Department of Urology The Third Xiangya Hospital of Central South University) Wang Long (Department of Urology The Third Xiangya Hospital of Central South University) Liu Jianye (Department of Urology The Third Xiangya Hospital of Central South University)
저널정보
한국생체재료학회 생체재료학회지 생체재료학회지 제27권
발행연도
2023.3
수록면
47 - 65 (19page)
DOI
10.1186/s40824-022-00328-9

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Gemcitabine (GEM) is one of the first-line chemotherapies for bladder cancer (BC), but the GEMs cannot recognize cancer cells and have a low long-term response rate and high recurrence rate with side effects during the treatment of BC. Targeted transport of GEMs to mediate cytotoxicity to tumor and avoid the systemic side effects remains a challenge in the treatment of BC.Based on a firstly confirmed biomarker in BC-protein tyrosine kinase 7 (PTK7), which is overexpressed on the cell membrane surface in BC cells, a novel targeting system protein tyrosine kinase 7 aptamer-Gemcitabine conjugate (PTK7-GEMs) was designed and synthesized using a specific PTK7 aptamer and GEM through auto-synthesis method to deliver GEM against BC. In addition, the antitumor effects and safety evaluation of PTK7-GEMs was assessed with a series of in vitro and in vivo assays.PTK7-GEMs can specifically bind and enter to BC cells dependent on the expression levels of PTK7 and via the macropinocytosis pathway, which induced cytotoxicity after GEM cleavage from PTK7-GEMs respond to the intracellular phosphatase. Moreover, PTK7-GEMs showed stronger anti-tumor efficacy and excellent biosafety in three types of tumor xenograft mice models.These results demonstrated that PTK7-GEMs is a successful targeted aptamer-drug conjugates strategy (APDCs) to treat BC, which will provide new directions for the precision treatment of BC in the field of biomarker-oriented tumor targeted therapy.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0